BioArts International is a new biotech startup focusing on unique, untapped markets in the multibillion dollar livestock, companion animal and human genomics industries. BioArts is based near San Francisco, with primary scientific labs in Beijing, livestock herds in North China, custom microengineering operations in London, and key scientific partnerships in Seoul, S. Korea, and other areas. All of these elements are working together to reinvent the animal reproduction and human genomics industries.

BioArts has assembled a world-class team of scientific, engineering and operational talent. We have re-organized and retained key staff, IP, know-how and capital equipment from affiliated projects dating back to 1997. Our vision is to use cutting edge technology to address high-margin biotech service niches at lowest possible cost. In China we have employed a highly skilled science and technology workforce, positioning the company to serve both a global market and the rapidly developing Chinese domestic market. In addition to our Chinese operations, BioArts' London subsidiary, RoBio Systems, is developing microengineered solutions for lines of business that are not currently cost-effective or even possible using conventional technology.

The first commercial service we are offering to the general public is dog cloning, through our Best Friends Again program. We will be cloning just five dogs for the general public using the most advanced technology available. The price for this service will be set by auction. BioArts International is the ONLY organization in the world with BOTH the know-how AND the legal right to clone dogs; we hold the exclusive rights to clone dogs and cats under patents filed worldwide following the cloning of Dolly the Sheep in 1996. Please visit the Best Friends Again website for more information on our dog cloning service, including how to participate in the auction.

BioArts is privately held.